14507-51-8

Basic information

• Product Name: 18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)- (9CI)
• Synonyms: 18,19-Dinor-17a-pregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy- (7CI,8CI)
• CAS NO: 14507-51-8
• Molecular Formula: C22H30 O2
• Molecular Weight: 326.479
• Mol File: 14507-51-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 462.8°Cat760mmHg
• Flash Point: 199.3°C
• Density: 1.11g/cm³
• CAS DataBase Reference: 18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)- (9CI)(14507-51-8)
• EPA Substance Registry System: 18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)- (9CI)(14507-51-8)

Safety Data

• Hazardous Substances Data: 14507-51-8(Hazardous Substances Data)

Usage

General Description

18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)- (9CI) is a chemical compound with the molecular formula C22H30O2. It is a synthetic steroid that belongs to the group of progestins. 18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)- (9CI) is used in the development of hormonal contraceptives and hormone replacement therapy. It acts on the progesterone receptor and has progestogenic, antiestrogenic, and antigonadotropic effects. It is also used in the treatment of menstrual disorders, endometriosis, and certain types of cancer. Additionally, it is involved in the regulation of the menstrual cycle and the maintenance of pregnancy.

Upstream product

• 3625-82-9 (+)-17β-hydroxy-13β-ethyl-3-methoxygona-1,3,5(10)-triene 
• 2322-77-2 13β-ethyl-3-methoxygona-2,5(10)-diene-17-one 
• 7487-88-9 magnesium sulfate 
• 14507-47-2 13β-ethyl-3-methoxygona-1,3,5(10)8-tetraen-17β-yl acetate 
• 14507-49-4 D-13β-ethyl-17β-hydroxy-3-methoxy-gona-2,5(10)-diene 
• 7443-72-3 18-methyl-3-methoxy-1,3,5(10),8-estratetraen-17β-ol 
• 2911-81-1 13β-Aethyl-3-methoxy-gonapentaen-(1.3.5(10).8.14)-ol-(17β)-acetat 
• 74-86-2 acetylene 
• 2322-77-2 13β-Ethyl-3-methoxy-gona-2,5(10)-dien-17-on 

Downstream Products

• 797-63-7 levonorgestrel 
• 13732-69-9 D-17β-acetoxy-13β-ethyl-17α-ethynyl-gon-4-en-3-one 
• 797-58-0 Norbolethone 
• 797-63-7 levonorgestrel 

Relevant articles and documents

Preparation method of levonorgestrel

The invention discloses a preparation method of levonorgestrel, and belongs to the technical field of medicine preparation and processing. According to the method, 18-methylestra-2,5(10)-diene-3-methoxy-17-ketone is used as an initial raw material, and the levonorgestrel disclosed by the invention is prepared by virtue of two steps of ethynylation and hydrolysis. According to the preparation method of the levonorgestrel, the defects of a traditional process are overcome and reaction conditions are mild; the method is high in overall conversion rate, easy and convenient to operate, suitable forindustrial production and wide in market prospect.

AN IMPROVED PROCESS FOR PREPARATION OF LEVONORGESTREL

The present invention provides an improved process for preparation of levonorgestrel (3) which comprises of hydrolysis of 13 β-ethyl-3-methoxy-17α-ethynyl-gona-2,5(10)-dien-17β- o1 (2) with an acid in aprotic solvent. The present invention also provides a novel process for purification of crude levonorgestrel (3) by recrystallization from N,N-dimethyl formamide- water; methanol-water mixture.

Synthesis of 13-alkyl-gon-4-ones

The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.